Levetiracetam add-on for drug-resistant focal epilepsy-Reference-Cited by-同舟云学术

Levetiracetam add-on for drug-resistant focal epilepsy

Published:2020-06-30 Issue:6 Volume:2020 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Mbizvo Gashirai K¹²,Chandrasekar Bharath³,Nevitt Sarah J⁴,Dixon Pete⁵,Hutton Jane L⁶,Marson Anthony G¹⁵⁷

Affiliation:

1. The Walton Centre NHS Foundation Trust; Liverpool UK

2. Muir Maxwell Epilepsy Centre, Centre for Clinical Brain Sciences, University of Edinburgh; Edinburgh UK

3. University of Liverpool; Liverpool UK

4. Department of Biostatistics; University of Liverpool; Liverpool UK

5. Department of Molecular and Clinical Pharmacology; Institute of Translational Medicine, University of Liverpool; Liverpool UK

6. Department of Statistics; University of Warwick; Coventry UK

7. Liverpool Health Partners; Liverpool UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference72 articles.

1. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group;Ben-Menachem;Epilepsia,2000

2. Evaluation of the efficacy and tolerability of UCB L059 (1500 mg b.i.d., 500 mg tablets) monotherapy in epileptic patients with complex partial onset seizures, having experienced improved seizure control under add-on treatment: a 60-week (maximum), double-blind, multicenter, responder-selected trial (phase III study, placebo comparator) UCB S.A. Pharma Sector

3. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy;Betts;Seizure,2000

4. A 24-week multicentered, double-blind, parallel group, add-on study to compare the efficacy and the tolerability of 2 oral daily doses of UCB L059 (2000 mg and 4000 mg tablets) with placebo in patients with refractory epilepsy, followed by a 24-week open-label active treatment UCB S.A. Pharma Sector

5. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial;Cereghino;Neurology,2000

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaginal candidiasis, predisposing factors, symptoms and treatment;SCT Proceedings in Interdisciplinary Insights and Innovations;2024-06-12

2. The effects of web-based animation-supported progressive relaxation exercises applied to individuals with epilepsy on fatigue and sleep quality: A randomized controlled study;Epilepsy & Behavior;2024-05

3. Cenobamate enhances the anticonvulsant effect of other antiseizure medications in the DBA/2 mouse model of reflex epilepsy;European Journal of Pharmacology;2024-01

4. Anticonvulsant Classes and Possible Mechanism of Actions;ACS Chemical Neuroscience;2023-11-10

5. Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function;Epilepsy & Behavior;2023-11